TWI333421B - - Google Patents
Download PDFInfo
- Publication number
- TWI333421B TWI333421B TW093134088A TW93134088A TWI333421B TW I333421 B TWI333421 B TW I333421B TW 093134088 A TW093134088 A TW 093134088A TW 93134088 A TW93134088 A TW 93134088A TW I333421 B TWI333421 B TW I333421B
- Authority
- TW
- Taiwan
- Prior art keywords
- salt
- cellulose
- agent
- ingot
- volatile
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 30
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 25
- 229920002678 cellulose Polymers 0.000 claims description 24
- 239000001913 cellulose Substances 0.000 claims description 24
- 235000010980 cellulose Nutrition 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 229920000609 methyl cellulose Polymers 0.000 claims description 15
- 239000001923 methylcellulose Substances 0.000 claims description 15
- 235000010981 methylcellulose Nutrition 0.000 claims description 15
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 14
- 239000003039 volatile agent Substances 0.000 claims description 14
- 229960001680 ibuprofen Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 238000004898 kneading Methods 0.000 claims description 8
- 238000000354 decomposition reaction Methods 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 229960000623 carbamazepine Drugs 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229910052797 bismuth Inorganic materials 0.000 claims description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims 1
- HDFRDWFLWVCOGP-UHFFFAOYSA-N carbonothioic O,S-acid Chemical group OC(S)=O HDFRDWFLWVCOGP-UHFFFAOYSA-N 0.000 claims 1
- 229960005222 phenazone Drugs 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 51
- 239000007787 solid Substances 0.000 description 37
- 239000007788 liquid Substances 0.000 description 24
- 239000008187 granular material Substances 0.000 description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 235000019645 odor Nutrition 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 230000004060 metabolic process Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 11
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- -1 polyethylene Polymers 0.000 description 9
- 239000000454 talc Substances 0.000 description 9
- 229910052623 talc Inorganic materials 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 229960001948 caffeine Drugs 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 238000009495 sugar coating Methods 0.000 description 6
- 239000007941 film coated tablet Substances 0.000 description 5
- 239000003595 mist Substances 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 238000000859 sublimation Methods 0.000 description 5
- 230000008022 sublimation Effects 0.000 description 5
- 229940105329 carboxymethylcellulose Drugs 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 4
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 3
- 229960000920 dihydrocodeine Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 3
- 229960004708 noscapine Drugs 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- KOQRETHOLOHQJI-YPZORMFFSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC KOQRETHOLOHQJI-YPZORMFFSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VMLAEGAAHIIWJX-UHFFFAOYSA-N propan-2-amine hydroiodide Chemical compound [I-].C(C)(C)[NH3+] VMLAEGAAHIIWJX-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- AZUCPFMKPGFGTB-UHFFFAOYSA-N 2,2-diiodopropane Chemical compound CC(C)(I)I AZUCPFMKPGFGTB-UHFFFAOYSA-N 0.000 description 1
- KHEDIYCQDPMFKF-UHFFFAOYSA-N 2-(sulfooxy)acetic acid Chemical compound OC(=O)COS(O)(=O)=O KHEDIYCQDPMFKF-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- UZEKTDVGUQCDBI-UHFFFAOYSA-N 2-propan-2-ylguanidine Chemical compound CC(C)NC(N)=N UZEKTDVGUQCDBI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- BIHAQRQLVORWSG-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)C1=CC=CC=C1.C(C=C/C(=O)O)(=O)O Chemical compound C(C1=CC=CC=C1)(=O)C1=CC=CC=C1.C(C=C/C(=O)O)(=O)O BIHAQRQLVORWSG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 240000003473 Grevillea banksii Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- KWGRBVOPPLSCSI-WPRPVWTQSA-N L-Ephedrine Natural products CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- CYGDSXFTXXFMNI-OTYYAQKOSA-N hydrofuramide Chemical compound C=1C=COC=1/C=N/C(C=1OC=CC=1)\N=C\C1=CC=CO1 CYGDSXFTXXFMNI-OTYYAQKOSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- TUIAQSKEFHFDRQ-UHFFFAOYSA-N n-chloro-n-methylformamide Chemical compound CN(Cl)C=O TUIAQSKEFHFDRQ-UHFFFAOYSA-N 0.000 description 1
- KPRZOPQOBJRYSW-UHFFFAOYSA-N o-hydroxybenzylamine Natural products NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- FTIMWVSQXCWTAW-UHFFFAOYSA-N ruthenium Chemical compound [Ru].[Ru] FTIMWVSQXCWTAW-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004035 thiopropyl group Chemical group [H]SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
九、發明說明: 【發明所屬之技術領域】 本發明係關於防止藥劑揮發 係關於防止藥劑揮發之固形製劑7固形製劑,更詳細地說, 有本身具有揮發性之藥劑或分解2及其製造方法,該製劑含 抑制因該藥劑昇華於藥劑保存j揮發性的藥劑,且可以 (whisker)或抑制來自製劑的臭味广器内發生之鬚狀結晶 【先前技術】 一般而言,固形製劑係密閉 器内。但是,已知a & π , & '、於玻璃瓶等藥劑保存容 疋巳知因為固形製劑 — 品保存時價值下降。 3之樂劑性質會造成製 比如,布洛芬(Ibupr〇fe 瓶等密閉容,隨時間㈣性㈣若保存於玻璃 、切日日)’使商品價值下降。 黃狀 P细w 降防止布洛芬產生鬚狀結晶之方法 Γ酮、將含f布洛芬之固形製劑與擇自聚乙稀基吼洛 ’元-K化_及I酸氫納中之_種或兩種以上 :密閉系中之方法(專利文獻〜將含有布洛芬之固形= 與乾燥劑-起保存於密閉系中之方法(專利讀2)、使用含 糖分及賦形劑及結合劑之糖衣液,對裸錠被覆裸錠重量 5〜60%之糖衣的方法(專利文獻3)、以糖類罩住之方法(專利 文獻4)之方法。 又,咖啡因等於保存時會有鬚狀結晶成長,使商品價值 下降造成問題。防止咖啡因等產生鬚狀結晶之方法已報告者 7042-6652-PF;chiumeow 5 1333421 有將含咖啡因之製劑、含有鬚狀結晶生成性藥劑含有製劑, 與碳、矽酸酐或(及)蒙脫石一起併存的方法(專利文獻5及 6 )、將昇華性藥物以含有環狀葡聚糖類之被覆劑被覆之方法 (專利文獻7)、於谷易發生鬚狀結晶之製劑配方中含有呈有 特定大小及比表面積之冷-1,4-葡聚糖粉末之方法(專利文 獻8)、於咖啡因類中配合制酸劑之方法(專利文獻9)。再者, 已報告者尚有於咖啡因(水合物)中添加活性碳或膨潤土之 方法(非專利文獻1)、及於無水咖啡因中混合白剛玉(wh i t e alumdum)或輕質矽酸酐(Aerosil 200 )之方法(非專利文獻 2 )。又’尚有將昇華性藥劑配合聚乙烯基吡咯烷酮類之方法 (專利文獻1 0 )。 此外’半胱胺酸類會有產生臭味的問題。防止因半胱胺 酸類造成藥劑臭味之方法已報告者有以含有糖分、賦形劑及 結合劑之糖衣液對裸錠被覆裸錠重量5〜60%之糖衣之方法 (專利文獻1 )、將L-半胱胺酸以乾式配合以降低臭味之方法 (專利文獻1 2 )。 但是,該等方法皆有有效果不夠,或是製程複雜的問題。 [專利文獻1 ]特開平8-193027號 [專利文獻2]特開平8-333247號 [專利文獻3]特開20 0 2-1 7955 9號 [專利文獻4]特開2002-241275號 [專利文獻5]特公昭56-37970號 [專利文獻6]特公昭56-53525號 [專利文獻7]特開昭61-1 291 38號 7042-6652-PF;Chiumeow 6 [專利文獻8]特開昭63-267733號 [專利文獻9]特開平2_85214號 [專利文獻1〇]特開2000-247870號 [專利文獻U]特開20 02-1 7 95 59號 [專利文獻12]特開2002-179559號 [非專利文獻丨]山田等,藥學雜誌,9 6 (丨〇), 1223-1228(1976) [非專利文獻2 ]湯淺等,藥劑學,41 ( 3 ),1 61 -1 71,( 1 9 81) 【發明内容】 [發明欲解決之課題] 欲提供一種技術,較先前技術更為簡便,能使含有本身 具有揮發性藥劑或分解物為揮發性之藥劑(以τ,將該等稱 為「揮發性藥劑」)之固形製劑中因揮發性所產生鬚狀結晶 或臭味減少。 [用以解決課題之手段] 本發明者等為解決上述課題,經過努力研究的結果, 現欲減低因揮發性藥劑而產生鬚狀結晶或臭味時,只要使 :含有揮發性藥劑之固形製劑中含有缓基甲基纖維素或 瓜以作為防止揮發藥劑即可,並完成了本發明。 亦即,本發明提供防止藥劑揮發之固形製劑,其特 虚二少含有本身具有揮發性藥劑或分解物為揮發性之藥 /、作為防止揮發藥劑之羧基甲基纖維素或其鹽。 7042-6652-PP;Chiume〇w 7 1333421 又’本發明提供防止藥 其特徵為:於至少含有本身且古固形製劑之製造方法’ 性之藥㈣μ 身”有揮發性藥劑或分解物為揮發 性之樂劑與作為防止揮發藥 # 劁之竣基甲基纖維素或其鹽之 回形製劑其製造方法中,將 合Μ π ^ ^ f基纖維素或其鹽使用於捏 1耘、造粒製程或覆膜製程中。 [發明之效果] 依本發明,可以減低 曰 句谭發性樂劑之固形製劑產生鬚 队培日日或臭味。 【實施方式】 ,本發明之防止藥劑揮發之固形製劑(以下,稱為「本發 月製劑」至)由揮發性藥劑及作為防止揮發藥劑之幾基尹其 纖維素或其鹽所構成。 土
其中,揮發性藥劑係指藥劑本身有揮發性或當藥劑之一 部分分解時其分解物具有揮發性者,比如,當含有該等藥劑 之固形製劑在保存時,藥劑會昇華而產生昇華性藥劑臭味之 具臭味藥劑。更具體地說,昇華性藥劑之例有布洛芬、吻啡 因(無水物、水合物等)、L-半胱胺酸等薄荷醇類、苯甲酸等 苯甲酸類、水楊酸甲酯等水楊酸類、D_樟腦等樟腦類、異丙 基安替比林、乙水楊胺、卡巴氮平(carbamazepine)等◊又, 發生臭味之具臭味藥劑的例子有L_半胱胺酸等半胱胺酸 類、鹽酸硫胺、硝酸硫胺、硝酸二硫胺、二硫硫胺、二苯硫 胺、辛硫胺、鹽酸呋喃硫胺(fursultiamineHC1)等維生素B 7042-6652-PF;Chiumeow 8 1333421 :二抗壞金酸、抗壞血酸飼等維生素c類' 生月醇妈、乙酸cU…生育醇辦等維生素e 該等昇華性藥劑或產生臭味之藥劑可使用i種或更多各種芬等。 又’本發明製劑所使㈣為防止揮㈣劑 甚 ” 將該等稱為「缓基甲基纖維素類」)。要 疋可以防止或減低揮發性藥劑揮發者即可,不_ = 體而言’叛基甲基纖維素類比如有罐基甲基纖維 二甲 基纖維素鉀、羧基甲基纖維㈣、縣甲基纖維 1 等可使用1種或更多種。 、等’該 該等羧基甲基纖維素類中較佳為羧基甲基纖維素鈉 基甲基纖維㈣有各㈣級,制在料覆職制時較佳 為使用低黏度的H該低黏度等級品其黏度範圍為以㈣ 黏度計⑵t、6G轉)測定m基甲基纖維素納1%水_之$ 度時,為卜2000CPS,更佳為卜1〇〇〇(:1^,特佳為卜5〇〇cps。 具體之製品名有CMC代謝爾(daicel)<型號11〇5>、cmc代謝 爾〈型號1107>、CMC代謝爾〈型號111〇>、日本藥典cmc代謝 爾〈型號1120〉、CMC代謝爾〈型號12〇5>、CMC代謝爾〈型號 120 7>、CMC代謝爾〈型號1210>、CMC日本藥典CMC代謝爾〈 型號1 220>(皆為代謝爾化學工業(股)製)等。 又,前述羧基曱基纖維素可以直接使用,亦可溶解於溶 劑或(及)使用懸浮溶液(以下,稱「CMC液」)。該CMC液十 所使用之溶劑只要使可以溶解或懸浮羧基甲基纖維素類之 溶劑即可’不特別限定,比如有水、醇或該等之混合液等。 該等CMC液其溶解性或黏度可藉由溫度、pH變化、離子添加 7042 -6652-PF;Chiumeow 9 1333421 等而改變。又,於該CMC液中亦可依需要而添加後述歟 結合劑、崩散劑、潤滑劑等。 / 本發明製劑除上述揮發性藥劑及作為防止揮發藥 缓基甲基纖維素類等必須成分以外,可藉由常用之^教= 粒、錠劑、膠囊劑等固形製劑的製造方法製造。此 較佳為於捏合製程'造粒製程或覆膜製程中使用竣基甲基镳 維素類,特別以使用於㈣製程中可使得到的㈣· 光澤,故較佳。 八有 本發明之捏合製程係指在常用之固形製劑製程中 搜拌造粒機、㈣造粒機等進行造粒之前,先將藥物 劑等(含結合劑、崩散劑等)捏合之製程。該捏合製程;;,錄 基甲基纖維素類係以直接或(及)於形成CMC液添加於荦物盘 賦形劑等中,或將㈣液以喷霧的方式添加。此時羧其甲: 纖維素類之添加量對藥物及賦形劑等之合計量,較'圭: 0.卜50質量%’又以〇· 2〜30質量〇/p杜.. '、、 貝里/〇更佳,特別以0. 5〜20質量 %更佳。此外,對於揮發性筚逾丨 、 m㈣Μ ’祕甲基纖維 添加量以0. 4〜60質量%較佳,又^ 又以卜40質量%更佳,特 2〜30質量%更佳。 又’本發明之造粒製程係於 〆 ,、才曰於㊉用之固形製劑製程中, 以流動層造粒機等將藥物與賦形 、蜱形劑等(含結合劑、崩散劑等) 進行造粒之製程。該造粒製程中, τ 緩基甲基纖維素類係以直 接或(及)於形成CMC液添加於藥机也^
於樂物與賦形劑等中,或將CMC 液以喷霧的方式添加。此時羧其田甘 羧基甲基纖維素類之添加量對藥 物及賦形劑等之合計量,較佳太n , 权佳為0.1〜50質量%,又以〇 2〜3〇 7042-6652-PF;Chiumeow 1333421 更佳’特❹ο·5〜2()質量%更佳。又,複基甲基纖維 之添加量對揮發性藥劑以〇_4〜60質量%為佳,以卜4〇 質量%更佳,特別以2 ~ 3 0質量%更佳。 又,本發明之覆膜製程係指於常用之固形製劑製程中, 將製造之顆粒或㈣以流動層造粒機或糖衣機等進行覆膜 =製程。該覆膜製程中,缓基甲基纖維素類係以直接或(及') :形成CMC液喷霧於顆粒或錠劑,以使顆粒或錠劑覆膜。此 T級基甲基纖維素類之添加量對藥物及賦形劑等之合計 里,較佳為0.1〜50質量%,又以0.2〜30質量%更佳,特別以 0質量/q更佳。又,羧基曱基纖維素類之添加量對揮發 2藥劑以0. 4〜60質量%為佳,以丨〜40質量%更佳,特別以2〜3〇 質量%更佳》 又,若有需要’亦可將上述羧基甲基纖維素類之覆膜内 側或外側或兩側以別的覆膜劑被覆。比如對鍵劑施以叛基甲 基纖維素類之覆膜’再施以糖衣覆臈等。又,於糖衣配方中 配合缓基甲基纖維素類亦可得到本發明製劑之效果,但較佳 為於顆粒或㈣等表面上僅錢基纖維素類之覆膜。依 此方式覆膜之本發明製劑較先前之經基甲基纖維素(卿c) 等覆膜劑所覆膜之固形製劑具有較佳的光澤。 又,本發明製劑在不妨礙本發明效果的範圍内,亦可添 加製劑領域一般所使用之賦形劑、結合劑、崩散劑、潤滑劑 等添加劑。 賦形劑比如有乳糖、殿粉、玉米激粉、α化殿粉、部分 α化殿粉、結晶纖維素、低取代度經基丙基纖維素、經基丙 11 7042-6652-pF;chiumeow 1333421 基纖維素、精製白糖、糖醇類、輕質矽酸酐、矽酸鈣、氧化 鈦、沉降碳酸鈣等。該等賦形劑可使用丨種或更多種。 結合劑比如有明膠、阿拉伯膠粉末、甲基纖維素、綾基 曱基纖維素、羧基曱基纖維素鈉、羥基丙基纖維素、羥基曱 基纖維素鈣、羧基曱基纖維素鈉、甲基丙烯酸共聚物等丙烯 酸衍生物、蟲膠、羧基乙烯基聚合物、羧基甲基澱粉鈉、羧 基曱基乙基纖維素、乙酸鄰苯二曱酸纖維素等。該等結合劑 可使用1種或更多種。 崩散劑比如有交聯羧甲纖維素鈉、交聯聚乙烯吡咯烷 酮、父聯不溶性聚乙烯基吡咯烷酮、羧甲纖維素鈣、羧基甲 土馬叔納馬鈴薯版粉、玉米澱粉、α化澱粉等。該等崩散 劑可使用1種或更多種。 潤滑劑比如有滑石、硬脂酸、硬脂酸鎂、蔗糖脂肪酸酯、 聚乙二醇等。該等潤滑劑可使用1種或更多種。 所得到之本發明防止藥劑揮發固之形製劑可製成細 粒、顆粒劑、錠劑等各種形態。該等防止藥劑揮發之固形製 劑可以保存於常用之玻璃瓶、ΡΤΡ包裝、鋁熱封包裝等藥劑 保存容器,且可減低保存時產生鬚狀結晶或臭味。 [實施例] 以下舉實施例對本發明更詳細說明,但本發明不限定於 該等實施例。 (實施例1) 固形製劑之製造(1): 於布洛芬450g、:氫可待因磷酸24g、d卜鹽酸甲基麻 7〇42-6652-PP;chiumeow 12 1333421 ^j- 上 汽素60g、碘化異丙醯胺6g、那可丁(Noscapine)48g、馬來 酸氯苯那敏7.5g、抗壞血酸300g、硝酸硫胺24g、無水咖啡 因75g中,加入結晶纖維素、輕質矽酸酐、乳糖、羥基丙基 纖維素等所構成之賦形劑1408. 5g,以得到粉體混合物。於 該等中加入純水進行濕式造粒後乾燥,製作成顆粒。將該顆 粒以圓錐形均質粉碎機(Powrex製)整粒後,加入滑石i 5g及 硬脂酸鎂12g並混合,以旋轉打錠機製成27〇mg/錠之裸錠。 對該裸錠以羥基丙基甲基纖維素(HPM◦、氧化鈦、水、 乙醇(7: 3 :20:70 )構成之薄膜覆膜劑(以下,稱為「白色HpMC鲁 液」以覆膜機(Hicoater)(佛洛依特產業(Freund
Corporation)製)喷霧,得到280mg/錠之膜衣錠(製造品ι)β 對該覆膜錠再以羧基甲基纖維素鈉(CMC代謝〈型號m〇>: 代謝爾化學工業(股))及水構成之薄膜覆膜劑(2. 5%水溶液) 喷霧,以得到282.5mg/錠、285mg/錠之膜衣錠。各稱為本發 明品1及本發明品2。 (比較例1) 比較固形製劑之製造(1 ) : ® 對實施例1得到之膜衣錠(製造品丨)以HPMC及水構成之 ,得到 282. 5mg/錠、285mg/ 及比較品2。 薄膜覆膜劑(2.5%水溶液)噴霧, 錠之膜衣錠。各稱為比較品1及 (實施例2) 固形製劑之製造(2): 240g中加入由結晶纖維 乳糖等所構成之賦形劑 於布洛芬450g及無水咖啡因 素、低取代度羥基丙基纖維素、 7042-6652-PF;Chiumeow 1333421 代=粉體混合物。於該等中加入緩基曱基纖維素納 ⑽c代謝爾〈型號1120>:代謝爾化學工業(股)製)之水容 液200g料捏合液(糊狀)進行濕式造粒後乾燥以製作為 顆粒。將該顆粒以圓錐形均質粉碎機(p〇wrex製)整粒後力 入滑石…及硬脂酸鎂6g並混合,以旋轉打旋機製成心 錢之裸錠。 對該裸鍵將白色HPMC液以覆膜機(Hic〇ater)(佛洛依特 產業(reund Corporation)製)喷霧’得到22〇mg/錠之膜衣 錠。稱為本發明品3。 (比較例2 ) 比較固形製劑之製造(2): 於布洛芬450g及無水咖啡因24〇g中加入由結晶纖維 素、低取代度經基丙基纖維素'乳糖等所構成之賦形劑 536g,得到粉體混合物。於該等中加入羧基甲基纖維素鈉 (CMC代謝爾〈型號1120>:代謝爾化學工業(股)製)之5%水溶 液200g作為捏合液(糊狀)進行濕式造粒後乾燥以製作為 顆粒。將該顆粒以圓錐形均質粉碎機(p〇wrex製)整粒後,加 入滑石18g及硬脂酸鎂6g並混合,以旋轉打錠機製成2i〇mg/ 錠之裸錠。 對該裸錠將白色HPMC液以覆膜機(Hic〇ater)(佛洛依特 產業(Freund Corporation)製)噴霧,得到22〇mg/錠之膜衣 錠。稱為比較品3。 (實施例3) 固形製劑之製造(3): 7042-6652-PF;Chiumeow 1333421 於布洛芬450g、二氫可待因磷酸24g、cU-鹽酸甲基麻 黃素60g、碘化異丙醯胺6g、那可丁(Noscapine)48g、馬來 酸氣苯那敏7. 5g、抗壞血酸300g、硝酸硫胺24g、無水咖啡 因7 5 g中,加入結晶纖維素、輕質石夕酸酐、乳糖、經基丙基 纖維素等所構成之賦形劑1 396g,以得到粉體混合物°對該 等以羧基曱基纖維素鈉(CMC代謝爾〈型號1120〉:代謝爾化 學工業(股)製)之2. 5%水溶液500g作為造粒液進行喷霧並造 粒後乾燥,製作成顆粒。將該顆粒以圓錐形均質粉碎機 (Powrex製)整粒後,加入滑石1 5g及硬脂酸鎂1 2g並混合, 以旋轉打錠機製成270mg/錠之裸錠。 對該裸錠將白色HPMC液以覆膜機(Hicoater)(佛洛依特 產業(reund Corporation)製)喷霧,得到280mg/錠之膜衣 錠。稱為本發明品4。 (比較例3 ) 比較固形製劑之製造(4): 於布洛芬450g、二氫可待因磷酸24g、cU-鹽酸甲基麻 汽素60g、峨化異丙醯胺gg、那可丁(N〇scapine)48g、馬來 酸氣苯那敏7. 5g、抗壞血酸300g、硝酸硫胺24g、無水咖哪 因75g中,加入結晶纖維素、輕質矽酸酐、乳糖、羥基丙基 纖維素等所構成之賦形劑丨396g,以得到粉體混合物。對該 等以羥基丙基纖維素之2. 5%水溶液5〇〇g作為造粒液進行喷 霧並造粒後乾燥,製作成顆粒。將該釋粒以圓錐形均質粉碎 機(Powrex製)整粒後,加入滑石15g及硬脂酸鎂i2g並混 °以紅轉打錠機製成27 Omg/錠之裸錠。 7042-6652-PF;Chiume〇w 15 1333421 對該裸錠將白色HPMC液以覆膜機(Hicoater)(佛洛依特 產業(Freund Corporation)製)喷霧,得到280mg/錠之膜衣 鍵。稱為比較品4。 (實施例4 ) 固形製劑之製造(4): 於布洛芬4 5 0 g中’加入由結晶纖維素、輕質矽酸酐所 構成之賦形劑1 9Og ’以得到粉末混合物。對該等以羧基甲基 纖維素鈉(CMC代謝爾〈型號1120〉:代謝爾化學工業(股)製) 之2.5%水溶液400g作為造粒液進行喷霧並造粒後乾燥,製 作成顆粒A。另外於二氫可待因磷酸24g、cU-鹽酸甲基麻黃 素60g、埃化異丙醢胺6g、那可丁(N〇scapine)48g、馬來酸 氣苯那敏7.5g、抗壞血酸300g、硝酸硫胺24g、無水咖啡因 75g中,加入結晶纖維素、低取代度羥基丙基纖維素、乳糖 所構成之賦形劑11 98. 5g ’以得到粉體混合物。對該等以經 基丙基纖維素之2.5%水溶液400g作為造粒液進行喷霧並造 粒後乾燥,製作成顆粒B。將顆粒a及顆粒B分別以圓錐形 均質粉碎機(Powrex製)整粒後混合,再加入滑石i5g及硬脂 酸鎂12g並混合,以旋轉打錠機製成27〇mg/錠之裸錠。 對該裸錠將白色HPMC液以覆膜機(Hic〇ater)(佛洛依特 產業(Freund Corporation)製)噴霧,得到28〇mg/錠之膜衣 錠。稱為本發明品5 » (實施例5 ) 固形製劑之製造(5): 於L-半胱胺酸240g及抗壞血酸3〇〇g中加入由結晶纖維 7042-6652-PF;Chiumeow 1333421 素、部分α化澱粉、輕質矽酸酐、羥基丙基纖維素等所構成 之賦形劑740g ’得到粉體混合物。於該等中加入滑石25g、 硬脂酸鎂15g並混合,以旋轉打錠機製成22Omg/錠之裸錠。 對該裸錠將白色HPMC液以覆膜機(Hicoater)(佛洛依特 產業(Freund Corporation)製)喷霧,得到230mg/鍵之膜衣 旋(製造品2)。對該膜衣錠再以羧基甲基纖維素鈉(日本藥典 CMC代謝爾〈型號H20〉:代謝爾化學工業(股)製)及水構成 之薄膜覆膜劑(2. 5%水溶液)喷霧,以得到235mg/錠、24Omg/ 錠之膜衣錠。各稱為本發明品6及本發明品7。 (比較例4 ) 比較固形製劑之製造(4): 於布洛芬450g中加入由結晶纖維素、輕質矽酸酐所構 成之賦形劑1 90g ’得到粉體混合物。於該等中加入羥基丙基 纖維素之2 · 5 %水溶液4 0 0 g作為造粒液進行喷霧,造粒之後 乾燥’以製作成顆粒C。另外於二氫可待因碗酸24g、dl -鹽 酸曱基麻黃素60g、碘化異丙醯胺6g、那可丁 (Noscapine)48g、馬來酸氯苯那敏7. 5g、抗壞血酸3〇〇g、 确酸硫胺2 4 g、無水咖》非因7 5 g中,加入結晶纖維素、低取 代度羥基丙基纖維素、乳糖所構成之賦形劑11 98. 5g,以得 到粉體混合物。對該等以羥基丙基纖維素之2. 5%水溶液400g 作為造粒液進行喷霧並造粒後乾燥,製作成顆粒D。將顆粒 C及顆粒D分別以圓錐形均質粉碎機(P〇wrex製)整粒後混 合’再加入滑石1 5 g及硬脂酸鎂1 2 g並混合,以旋轉打錠機 製成270mg/錠之裸錠。 7042-6652-PF;Chiumeow 17 丄333421 對該裸鍵將白色HPMC液以覆膜機(Hicoater)(佛洛依特 產業(Freund Corporation)製)喷霧,得到280mg/錠之膜衣 錠。稱為比較品5。 (比較例5) 比較固形製劑之製造(5 ): 對實施例所得到之膜衣錠(製造品2)以HpMC與水構成之 溥膜覆膜劑(2. 5%水溶液)噴霧,得到235mg/錠、24〇mg/錠之 膜衣錠。各稱為比較品6及比較品7。 (試驗例1) 固形製劑之保存試驗: 將本發明品1〜5及比較品1〜5之固形製劑放入無色透明 之玻璃瓶並密閉之,於5m#左ιη 0 μ J ^ 保存ίο日後,觀察玻璃瓶内壁 之霧狀物。又’霧狀物之評價基準如下。 〈霧狀物之評價基準> (評價)(内容) ~ 完全無霧狀物。 土: 幾乎無霧狀物。 +: 有霧狀物。 ++ : 認為有強烈霧狀物。 +++: 認為有強烈顯著霧狀物。 [表1 ]
7042-6652-pp;Chiumeow 18 1333421 t (試驗例2 ) 固形製劑光澤之發生試驗: 依以下基準對本發明品1、2、6、7及比較品 丄、2、6、 在試驗例1保存前及後進行固形製劑之光澤比較。 1乐存前後 固形製劑的光澤沒有變化。又,光澤之評價基準如下 〈光澤之評價基準〉 [表2 ] 本發明品7
(評價) (内容) 土 : 幾乎無光澤。 + : 有光澤。 ++ : s忍為有強烈光澤。 固形製劑臭味之發生試驗: 將本發明品6及7及比較品…之檢體玫入,色透 玻璃瓶内並密閉之,於5。 、 保存1〇日後,對將玻 開後蚵間的臭味進行評價。χ 〈臭味之評價基準〉 臭味之“基準如下。 (評價)(内容) 幾乎無臭味。 有臭味。 有強烈臭味。 7042-6652-pp;Chiume〇w 19 1333421 [表3 ] 本發明品6 本發明品7 + 士 比較品6 比較品7 + + + + [產業之可利用性] 依本發明,可以防止或降低含有揮發性藥劑之固形製劑 中藥劑揮發。 故,本發明製劑可以防止於藥劑保存容器中發生鬚狀結 晶或臭味,可以提高製劑之商品價值。 【圖式簡單說明】 無。 【主要元件符號說明】 無0 7042-6652-PF;Chiumeow 20
Claims (1)
- 丄 修正曰期:99·7_8 第093134088號中文申請專利範圍修正本 I*™·"™———— .. 十、申請專利範圍:卜1年7月(Γ : “ 1.—㈣基甲基纖維素或其鹽之用於防止揮 : = :,徵為:至少本身為揮發性之藥劑或其分解 ==之樂劑在作為防止揮發藥劑的製造方法中,添加 解:“發1素士其鹽’其中該本身為揮發性之藥劑或其分 解物為揮發性之樂劑包含下列藥劑(Α)及/或⑻: (Α):華性藥劑’擇自由布洛芬⑻ 『、薄何醇類、苯甲酸類、水楊酸類、異丙基安 (slopropylantipyrine)、^^楊胺 whenzalnlde)、卡巴氣 + (carbamazepine)等所構成群中的1種或以上; (B)發生臭味之藥薇丨,挥ώ 維生素C類、維生素Ε類“胺酸類、維生㈣類、 素Ε類、布洛芬所構成群中的1種或以上。 ,伞,=中請專利範圍第1項之《甲基纖維素或其鹽之用 幾基基纖維素或其鹽為擇自㈣基甲基纖維素、 基甲基纖維㈣、缓基甲基纖維素鈉 所構成群中1種或更多種。 3. 如申請專利範圍第1或2項之幾基,基纖維素… 之用途’係減低藥劑保存容器内發生鬚狀結晶。 、 4. 如申„月專利耗圍第!或2項之羧基曱基 之用途,係減低臭味之發生。 亨飞,、麗 項之羧基甲基纖維素或 其鹽係使用於捏合製程 項之羧基尹基纖維素或 其鹽係使用於造粒製程 其鹽 〇 並鹽 /、 《nzL 5. 如申請專利範圍第1或2 之用途,其中羧基甲基纖維素或 6. 如申請專利範圍第1或2 之用途,其中羧基甲基纖維素或 7042-6652-PF2 21 1333421 之用 7.如申請專利範圍第1或2項之羧基甲基纖維素或其鹽 途,其中羧基甲基纖維素或其鹽係使用於覆膜製程。 7042-6652-PF2 22
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003399851A JP5248733B2 (ja) | 2003-11-28 | 2003-11-28 | 揮散防止型固形製剤およびその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200518774A TW200518774A (en) | 2005-06-16 |
TWI333421B true TWI333421B (zh) | 2010-11-21 |
Family
ID=34724286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093134088A TW200518774A (en) | 2003-11-28 | 2004-11-09 | Volatile proof solid preparation and producing method thereof |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5248733B2 (zh) |
KR (1) | KR20050052361A (zh) |
CN (1) | CN1636553A (zh) |
TW (1) | TW200518774A (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI367755B (en) * | 2005-05-20 | 2012-07-11 | Sankyo Co | Film coated product |
JP2007131561A (ja) * | 2005-11-09 | 2007-05-31 | Ss Pharmaceut Co Ltd | 経口固形製剤及びその製造法 |
JP5201819B2 (ja) * | 2006-11-22 | 2013-06-05 | エスエス製薬株式会社 | 固形組成物 |
TWI392505B (zh) * | 2006-11-22 | 2013-04-11 | Ssp Co Ltd | 固形組合物 |
JP2008127350A (ja) * | 2006-11-22 | 2008-06-05 | Ss Pharmaceut Co Ltd | 臭いを防止した固形組成物 |
EP2100606A4 (en) * | 2006-12-07 | 2009-12-30 | Daiichi Sankyo Co Ltd | COATED PREPARATION OF A FILM HAVING IMPROVED STABILITY |
TWI482641B (zh) | 2006-12-07 | 2015-05-01 | Daiichi Sankyo Co Ltd | 含有低取代度羥丙基纖維素之醫藥組成物 |
JP5733930B2 (ja) * | 2009-09-09 | 2015-06-10 | 武田薬品工業株式会社 | 固形製剤 |
KR102209574B1 (ko) * | 2019-10-08 | 2021-02-01 | 주식회사 에스엔비아 | 싸이올 화합물 소취용 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61129138A (ja) * | 1984-11-16 | 1986-06-17 | Takeda Chem Ind Ltd | 被覆製剤 |
GB8629567D0 (en) * | 1986-12-10 | 1987-01-21 | Boots Co Plc | Therapeutic agents |
US4837031A (en) * | 1987-09-17 | 1989-06-06 | Mallinckrodt, Inc. | Compositions containing ibuprofen |
JP2591235B2 (ja) * | 1989-03-30 | 1997-03-19 | 吉富製薬株式会社 | アルキルシステインまたはその酸付加塩を含有する安定な錠剤 |
JP3172749B2 (ja) * | 1992-02-17 | 2001-06-04 | ライオン株式会社 | イブプロフェン含有製剤 |
JPH0656677A (ja) * | 1992-08-03 | 1994-03-01 | Lion Corp | 制酸剤組成物 |
JPH08310953A (ja) * | 1995-05-22 | 1996-11-26 | Lion Corp | 固形組成物 |
US6248391B1 (en) * | 1997-07-16 | 2001-06-19 | Bpsi Holdings, Inc. | Bright white film coatings and film coating compositions therefor |
HUP0104606A3 (en) * | 1998-12-18 | 2003-01-28 | Basf Ag | A pharmaceutical mixture comprising a profen |
DE10003757A1 (de) * | 2000-01-28 | 2001-08-02 | Knoll Ag | Ibuprofen-Wirkstoffzubereitung |
-
2003
- 2003-11-28 JP JP2003399851A patent/JP5248733B2/ja not_active Expired - Lifetime
-
2004
- 2004-11-09 TW TW093134088A patent/TW200518774A/zh not_active IP Right Cessation
- 2004-11-25 KR KR1020040097230A patent/KR20050052361A/ko not_active Application Discontinuation
- 2004-11-26 CN CNA2004100961166A patent/CN1636553A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
JP5248733B2 (ja) | 2013-07-31 |
JP2005162619A (ja) | 2005-06-23 |
CN1636553A (zh) | 2005-07-13 |
KR20050052361A (ko) | 2005-06-02 |
TW200518774A (en) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5278708B2 (ja) | ナテグリニド含有親水性医薬製剤 | |
TWI283573B (en) | Nateglinide containing preparations | |
TWI526210B (zh) | Oral pharmaceutical composition | |
CN106102716A (zh) | 雄激素受体拮抗剂的固体药物组合物 | |
JP5201819B2 (ja) | 固形組成物 | |
TWI333421B (zh) | ||
CN101103965A (zh) | 含有无定形头孢托仑酯的稳定固体制剂及其制备方法 | |
JP2018039823A (ja) | メントールウィスカーの析出を抑制する方法 | |
JP2010189443A (ja) | 揮散防止型固形製剤およびその製造方法 | |
JP6367042B2 (ja) | ボリコナゾールを含む医薬組成物 | |
TW200306199A (en) | Stable salts of O-acetylsalicylic acid with basic amino acids II | |
JP2008094845A (ja) | 医薬錠剤 | |
JP2013043834A (ja) | 溶出改善固形製剤 | |
CN105748421B (zh) | 一种含盐酸曲唑酮的缓释片及其制备方法 | |
EA015440B1 (ru) | Твердая лекарственная форма, содержащая полиморфную форму 1 клопидогрела гидросульфата | |
JPWO2007046411A1 (ja) | イソキサゾール化合物の安定化方法 | |
JP6461496B2 (ja) | 解熱鎮痛製剤 | |
WO2005000290A1 (ja) | イブプロフェン含有フィルムコーティング錠剤 | |
JP5825686B2 (ja) | 難水溶性薬物含有微粒子造粒物の製造法 | |
JP4171204B2 (ja) | 成分の昇華を抑制した経口固形製剤 | |
JPWO2020111089A1 (ja) | 医薬組成物 | |
JP2003183181A (ja) | 昇華性成分含有製剤 | |
JP6654682B2 (ja) | 解熱鎮痛医薬品 | |
TWI252755B (en) | Medical composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid | |
TWI392505B (zh) | 固形組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |